3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
4
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Immunoblastic Lymphadenopathy
2
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
160
Rituximab
82
Peripheral Blood Stem Cell Transplantation
78
fludarabine phosphate
75
Etoposide
69
Filgrastim
67
Methotrexate
59
Cytarabine
58
Vincristine
50
Mycophenolic Acid
50
Whole-Body Irradiation
48
Radiotherapy
43
Cyclosporine
43
Busulfan
42
Tacrolimus
40
Melphalan
39
Dexamethasone
37
Prednisone
36
Doxorubicin
36
Antilymphocyte Serum
36
fludarabine
31
blinatumomab
27
Methylprednisolone
24
Granulocyte Colony-Stimulating Factor
22
Carmustine
22
Cord Blood Stem Cell Transplantation
21
Calcium Dobesilate
18
CT-P10
18
Inotuzumab Ozogamicin
16
sargramostim
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Burkitt Lymphoma
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled